Since authorised in 2014, tucidinostat was regarded as a next-line and subsequent therapy for PTCL clients in China. Medical trials and preclinical scientific studies in various hematological malignancies and strong tumors is in development. The intention of the present stage IIb review was To judge the efficacy and safety of https://ammonz221mxh4.blogolenta.com/profile